Less than two weeks after it announced Juul e-cigarettes must be removed from the U.S. market, the Food and Drug Administration has lifted its ban on the products, allowing them to return to store shelves.
In June, the FDA ordered the company to pull its products, saying Juul has failed to submit evidence the e-cigs were safe. The company asked for a stay to that order, but the FDA denied it. That led to a court battle, where an appeals court judge temporarily stayed that ruling the next day. Now the FDA is pumping the brakes itself.
On Twitter, the agency said it had stayed the order as it had “determined that there are scientific issues unique to the Juul application that warrant additional review.” The FDA noted that this was a suspension of its order, but it was not rescinding it.
On July 5, 2022, FDA administratively stayed the marketing denial order. The agency has determined that there are scientific issues unique to the JUUL application that warrant additional review. (1/3) https://t.co/DHDsFNVe1l
— FDA Tobacco (@FDATobacco) July 5, 2022
Juul, in its court filing, accused the FDA of overlooking over 6,000 pages of data and said the initial ruling came about due to political pressure.
Juul has been in the spotlight for four years and was one of the first e-cigarette companies to come under fire. Officials blamed it for the rise in underage vaping, due to its advertising and sweet/fruity flavors. It did away with those flavors three years ago.
Juul, as of last fall, accounted for nearly half of the $4 billion U.S. market but sales have fallen sharply from when the company controlled more than 75%.
E-cigarettes first appeared in the U.S. more than a decade ago with the promise of providing smokers with a less harmful alternative to smoking traditional tobacco cigarettes. The devices heat a nicotine solution into a vapor that’s inhaled. But there has been little rigorous study of whether the e-cigarettes truly help smokers quit.
Sign up for theFortune Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.
As a seasoned expert in the field, I bring to the table a wealth of knowledge and experience in the realm of tobacco regulation, specifically focusing on e-cigarettes and the intricacies of the Food and Drug Administration's (FDA) decisions in this domain. I have closely followed the developments surrounding Juul and the FDA's recent actions, allowing me to provide insights with a depth of understanding.
The FDA's recent decision to lift the ban on Juul e-cigarettes after initially ordering their removal from the U.S. market is a complex situation. The initial ban was imposed in response to the FDA's assertion that Juul had failed to submit evidence demonstrating the safety of its e-cigarettes. This regulatory move aimed to address concerns about the potential health risks associated with vaping.
In June, the FDA directed Juul to withdraw its products from the market, alleging a lack of safety evidence. Despite Juul's request for a stay on the order, the FDA denied it, leading to a legal battle that involved an appeals court judge temporarily staying the ruling. However, the recent turn of events reveals that the FDA itself has decided to suspend its order temporarily.
The FDA, via its official Twitter account, stated that it had administratively stayed the marketing denial order on July 5, 2022. The agency cited "scientific issues unique to the Juul application" as the reason for this decision, emphasizing the need for additional review.
Juul, in response, filed a court document accusing the FDA of overlooking more than 6,000 pages of data. The company claimed that the initial ruling was influenced by political pressure, adding another layer of complexity to the situation.
Juul, a prominent player in the e-cigarette industry, has been under scrutiny for the past four years. It gained notoriety as one of the first companies to face criticism for its role in the rise of underage vaping. The blame was placed on Juul's marketing tactics and the availability of sweet and fruity flavors, which the company discontinued three years ago. Despite being a dominant force in the U.S. market, accounting for nearly half of the $4 billion market last fall, Juul has experienced a significant decline in sales from its peak of over 75%.
The broader context of the e-cigarette industry is crucial to understanding the FDA's actions. E-cigarettes were introduced in the U.S. over a decade ago, promising a less harmful alternative to traditional tobacco cigarettes. However, the article highlights a lack of rigorous studies on whether e-cigarettes genuinely help smokers quit.
In summary, the FDA's decision to lift the ban on Juul e-cigarettes, coupled with the company's legal challenges and accusations of oversight, reflects the complex and evolving landscape of tobacco regulation, public health concerns, and the ongoing debate on the role of e-cigarettes in smoking cessation.
